Trials / Terminated
TerminatedNCT04145700
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 12 Months – 29 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults. This trial is part of the CAMPFIRE master protocol (NCT05999994) which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ramucirumab | Ramucirumab given IV |
| DRUG | Gemcitabine | Gemcitabine given IV |
| DRUG | Docetaxel | Docetaxel given IV |
Timeline
- Start date
- 2020-03-04
- Primary completion
- 2023-02-23
- Completion
- 2023-02-23
- First posted
- 2019-10-31
- Last updated
- 2023-09-13
- Results posted
- 2023-09-13
Locations
56 sites across 10 countries: United States, Australia, Belgium, France, Germany, Italy, Japan, Netherlands, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04145700. Inclusion in this directory is not an endorsement.